Enhancing CAR T cells with small molecule targeted protein modulation is the scientific foundation of DeCART. Our goal is to modify the underlying CAR T cell biology ex vivo using small molecules to control levels of certain proteins in the T cells. This ex vivo control of protein levels enhances the phenotype of the T cells, referred to as drug-enhanced CAR T cells, which we believe improves CAR T cell therapies and cancer patient outcomes.
DeCART Therapeutics is a biotechnology company founded by a team of scientific and business leaders including Carl H. June, M.D., Joseph A. Fraietta, Ph.D., and Xianxin Hua, M.D., Ph.D. from the University of Pennsylvania; Dana M. Hammill, M.S., M.B.A., formally from the University of Pennsylvania and now Chief Operating Officer of DeCART; and, Arthur T. Sands, M.D., Ph.D. and Pierre Beaurang, Ph.D. from Nurix Therapeutics.
Company Details
- Founded
- -
- Industry
- Biotechnology
- Website
- https://decart.com/
Decart Therapeutics Questions
Decart Therapeutics's website is https://decart.com/
Decart Therapeutics's LinkedIn profile is https://www.linkedin.com/company/decarttx
Decart Therapeutics's industry is
Biotechnology
Decart Therapeutics's top competitors are
Rnr Biomedical Solutions,
Decart Ltd,
Nurix Therapeutics,
Vigil Neuroscience,
Nitrase Therapeutics,
Decart,
Gsk.
Decart Therapeutics's categories are Biotechnology
Decart Therapeutics's founding year is 2020
